The WHO and NCEP/ATPIII definitions of the metabolic syndrome in postmenopausal women: Are they so different?

Metabolic Syndrome and Related Disorders

Volumn 4, Issue 1, 2006, Pages 17-27

  Piché, Marie Ève ^a,b   Weisnagel, S John ^b,c,d   Corneau, Louise ^a   Nadeau, André ^c   Bergeron, Jean ^b   Lemieux, Simone ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b Lipid Research Center   (Canada)

^c Diabetes Research Unit   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY FAT DISTRIBUTION; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POSTMENOPAUSE; POSTPRANDIAL STATE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WORLD HEALTH ORGANIZATION;

EID: 33646166112     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2006.4.17     Document Type: Article

References (36)

1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
2. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 1998;148:958-966.
3. Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992;24:465-468.
4. Groop L, Ekstrand A, Forsblom C, Widen E, Groop PH, Teppo AM, Eriksson J. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993;36:642-647.
5. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study Diabetes 1998;47:793-800.
6. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999;22:C25-C30.
7. Meigs JB. Invited commentary. Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000;152:908-911.
8. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
9. Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 1998;20:157-172.
10. Bouchard C. Genetics and the metabolic syndrome. Int J Obes Relat Metab Disord 1995;19:S52-S59.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
13. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003;26:575-581.
14. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
15. Lohman T, Roche A, Martorel R. Standardization of anthropometric measurements. In: Lohman T, Roche A, Martorel R, eds. The Airlie (VA) Consensus Conference. Champaign, IL: Human Kinetics; 1988:39-80.
16. Major GC, Piché ME, Bergeron J, Weisnagel SJ, Nadeau A, Lemieux S. Energy expenditure from physical activity and the metabolic risk profile at menopause. Med Sci Sports Exerc 2005; 37:204-212.
17. Sjöstróm L, Kvist H, Cederblad A, Tylen U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. Am J Physiol 1986;250:E736-E745.
18. Richterich R, Dauwalder H. [Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method]. Schweiz Med Wochenschr 1971;101:615-618.
19. Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 1971;33:732-738.
20. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
21. Couillard C, Després JP, Lamarche B, Bergeron J, Gagnon J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001;21:1226-1232.
22. Ridker PM, Bassuk SS, Toth PP. C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep 2003;5:341-349.
23. Kirkendall WM, Burton AC, Epstein FH, Freis ED. Recommendations for human blood pressure determination by sphygmomanometers. Circulation 1967; 36:980-988.
24. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
25. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33:363-374.
26. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708-7Z3.
27. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very-low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med 2001;11:170-176.
28. Pascot A, Després JP, Lemieux I, Bergeron J, Nadeau A, Prud'homme D, Tremblay A, Lemieux S. Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 2000;43:1126-1135.
29. Després JP, Ferland M, Moorjani S, Nadeau A, Tremblay A, Lupien PJ, Thériault G, Bouchard C. Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women. Arteriosclerosis 1989;9:485-492.
30. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004;28:674-679.
31. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105: 564-569.
32. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-636.
33. Vidal J, Morinigo R, Codoceo VH, Casamitjana R, Pellitero S, Gomis R. The importance of diagnostic criteria in the association between the metabolic syndrome and cardiovascular disease in obese subjects. Int J Obes Relat Metab Disord 2005;29:668-674.
34. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, Ermini G, Savorani G, Zocchi D, Melchionda N. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med 2004; 21:383-387.
35. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Mehta R, Franco A, Olaiz G, Rull JA. The metabolic syndrome: a concept hard to define. Arch Med Res 2005; 36:223-231.
36. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-1257.